PA-RELIEF-THERAPEUTICS
RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTC:RLFTF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that FDA has granted an Expanded Access Protocol for treatment of Respiratory Failure in COVID-19 with RLF-100 (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP). The protocol makes treatment available to patients who have exhausted standard therapies and are not eligible for the current phase 2/3 trial of RLF-100 because of confounding medical conditions and specifically makes the treatment available to pregnant women. Although the drug remains under investigation, rapid recovery from respiratory failure in COVID-19 has been seen in patients treated under FDA Emergency Use authorization.1
The expanded access protocol may be viewed on www.clinicaltrials.gov NCT04453839. Physicians who wish to enroll their patients in the protocol must submit the protocol to their local investigational review board and file FDA form 1572 with NeuroRx, Inc. Further information may be obtained from expandedaccess@neurorxpharma.com .
“By granting this Expanded Access protocol, FDA has made a potentially lifesaving drug immediately available to critically ill patients who have no other available treatment,” said Dr. Jonathan C. Javitt, MD, MPH, NeuroRx’s CEO. “We thank the FDA’s pulmonary division for its rapid and proactive implementation of the Coronavirus Treatment Acceleration Program, and we aspire to demonstrate broad safety and efficacy for RLF-100 in our ongoing clinical trial .”
The SARS-CoV-2 coronavirus that causes COVID-19 attacks the body by entering the small population of Alveolar Type II cells in the lung.2 Without Type II cells, the lung cannot transmit oxygen, which why the coronavirus causes acute respiratory failure. 50 years of scientific research demonstrates that VIP binds specifically to the Type II cell and protects that cell against cytokines (inflammatory molecules) and a wide array of toxic and infectious injuries.”3
About RELIEF THERAPEUTICS Holding AG
The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief Therapeutics also holds a U.S. patent4 for RLF-100 and proprietary manufacturing processes for its synthesis.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF (ISIN: CH0100191136).
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials.
Disclaimer : This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
1 Youssef JG, Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide doi: 10.20944/preprints202007.0178.v1
2 Mason R. Pathogenesis of COVID-19 from a Cell Biologic Perspective. Eur Respir J. April 9 Epub ahead of print. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144II60/
4 US 8,178,489 Formulation for Aviptadil
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daikin Leverages DataXstream’s OMS+ to Take Customer Experience to New Heights2.12.2025 16:03:00 CET | Press release
SAP-native platform will empower Daikin to reduce complexity, elevate the in-store/online customer experience, and optimize order accuracy across all locations DataXstream LLC, an SAP® Endorsed App partner developing intelligent solutions for SAP sales and distribution, announced today that Daikin Comfort Technologies North America, Inc. (Daikin), a subsidiary of Daikin Industries Ltd. and leading HVAC manufacturer, has selected its OMS+ platform to deliver real-time point-of-sales capabilities, along with an intuitive, streamlined order management to transform Daikin’s in-store and online customer experience. Leveraging SAP solutions, Daikin and DataXstream are elevating the way customers engage with Daikin’s stores and brand by delivering unparalleled, consistent point-of-sale capabilities, along with real-time visibility of orders and inventory across all sales channels. “Customers want a consistent and responsive experience, regardless of where they place their order,“ said Tim Yat
Halo Infinite and Elysium Senior Concept Designer Ben Mauro Launches HUXLEY: The Oracle - Sci-Fi Prequel Debuts as #1 Amazon New Release2.12.2025 16:00:00 CET | Press release
Ben Mauro, the acclaimed concept artist and worldbuilder behind Halo Infinite, Call of Duty, Elysium, and The Predator, today announced the US release of HUXLEY: The Oracle. The book, serving as the narrative prequel to Mauro’s expanding HUXLEY universe, has already reached #1 in Amazon’s New Releases for Conceptual Art based on pre-orders alone. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202609807/en/ HUXLEY: The Oracle Cover illustration HUXLEY: The Oracle departs from the graphic novel format in the first book, adopting an immersive narrative art book format that pairs cinematic, full-page illustrations alongside storytelling. Using a format familiar to readers of Simon Stålenhag’s Tales from the Loop, the book places world-building at the forefront, delivering a large-scale, atmospheric introduction to the world of HUXLEY that is fitting to the new story. HUXLEY: The Oracle unites a "dream team" of industry heavyw
Ullevaal Stadium Among the First in the World to Install FIFA Quality Pro Certified LED Lighting System2.12.2025 15:15:00 CET | Press release
A newly installed, state-of-the-art LED lighting system at Ullevaal Stadium has transformed the playing, viewing, and entertainment experience for athletes and spectators, and has made Norway’s national stadium one of the few in the world with FIFA Quality Pro Certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201171907/en/ The state-of-the-art TLC for LED® lighting system at Ullevaal Stadium has made Norway’s national stadium one of the few in the world with FIFA Quality Pro Certification. Home to Norway’s national football team, Ullevaal Stadium opened in 1926 and has a rich history of hosting significant sporting and entertainment events. When stadium ownership at the Football Association of Norway (NFF) decided to upgrade the venue’s lighting, they envisioned a system with the most advanced LED technology for the best possible playing, viewing, and entertainment experience. “Our main priorities for the new
Logical Intelligence Achieves 76 Percent on Putnam Benchmark, Highlighting Shift Beyond Large Language Models to Language-free, Mathematically Grounded Models2.12.2025 15:15:00 CET | Press release
Over the last decade, artificial intelligence (AI) has been largely built around large language models (LLMs). These systems are based on a language and guess words in a chain in the form of tokens. As a result, they frequently hallucinate and require vast compute and power infrastructure to solve tasks. The moment systems like public safety, national infrastructure, and industrial automation need logic, LLMs break and introduce safety risks. Token-free language independent models represent a new direction for AI. They do not predict words. They search for correct solutions and require less compute. Logical Intelligence is the first company building exclusively around mathematically derived, non autoregressive EBM (Energy Based Model) reasoning. Today, Logical Intelligence announced that its Aleph tool achieved a 76 percent score on the Putnam Benchmark, one of the most demanding mathematical reasoning tests in artificial intelligence. The benchmark measures a model’s ability to solve
MUSASHI JAPAN Launches “Gift Campaign 2025” - A Holiday Tradition Honoring Craftsmanship Through Meaningful Gifts2.12.2025 15:07:00 CET | Press release
MUSASHI JAPAN by TAIMATSU announces the return of its year-end celebration, Gift Campaign 2025, a seasonal tradition that transforms holiday shopping into an experience of appreciation, craftsmanship, and cultural generosity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202812444/en/ Rather than focusing on discounts, MUSASHI embraces the philosophy that true value lies in tools that last and in the gestures that accompany them. This year’s campaign invites customers to discover gifts that enrich their craft in the kitchen, each thoughtfully chosen to support the longevity and performance of every Musashi blade. Inspired by the Japanese principle of omotenashi, the campaign offers customers tiered gifts based on their total purchase amount, ensuring that every contribution is met with gratitude and purpose. From December 2 to December 25, 2025, customers shopping in MUSASHI JAPAN stores will receive: Tier 1: Oil and Rus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom